A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer

被引:23
作者
Nixon, N. A. [1 ]
Hannouf, M. B. [2 ,3 ]
Verma, S. [1 ]
机构
[1] Univ Calgary, Cumming Sch Med, Dept Oncol, 1331 29th St NW, Calgary, AB T2N 4N2, Canada
[2] Western Univ, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada
[3] Western Univ, Ivey Sch Business, London, ON, Canada
关键词
Value; Cost-effectiveness; Human epidermal growth factor receptor-2 (HER2); Breast cancer; COST-EFFECTIVENESS ANALYSIS; ADJUVANT TRASTUZUMAB THERAPY; LAPATINIB PLUS CAPECITABINE; PHASE-III TRIAL; MONOCLONAL-ANTIBODY; ECONOMIC-EVALUATION; OPEN-LABEL; HER2; CHEMOTHERAPY; PERTUZUMAB;
D O I
10.1016/j.ejca.2017.10.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cost of cancer drugs continues to escalate with the rapid development and approval of novel therapies, especially over the course of the last decade. In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the survival benefits gained by new treatments have been undeniably substantial. It is important to assess the financial value of these therapies for decision making at both the societal and individual level. This information is key for managing resources in resource-limited health care systems, while at the same time supporting patient decision-making and conversations between patient and physicians on cost versus benefit. In this article, we perform a systematic review of cost-effectiveness analyses that have been completed to date on HER2-targeted agents, focussing on those that correlate with standard of care therapy. Our discussion also highlights potential strategies to overcome several limitations associated with measuring value for anticancer drugs. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:72 / 81
页数:10
相关论文
共 68 条
[51]  
Pan-Canadian Oncology Drugs Review, TRAST KADC MBC FIN E
[52]   Does comparative effectiveness research promote rationing of cancer care? [J].
Peppercorn, Jeffrey ;
Zafar, S. Yousuf ;
Houck, Kevin ;
Ubel, Peter ;
Meropol, Neal J. .
LANCET ONCOLOGY, 2014, 15 (03) :E132-E138
[53]   Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 [J].
Perez, Edith A. ;
Romond, Edward H. ;
Suman, Vera J. ;
Jeong, Jong-Hyeon ;
Sledge, George ;
Geyer, Charles E., Jr. ;
Martino, Silvana ;
Rastogi, Priya ;
Gralow, Julie ;
Swain, Sandra M. ;
Winer, Eric P. ;
Colon-Otero, Gerardo ;
Davidson, Nancy E. ;
Mamounas, Eleftherios ;
Zujewski, Jo Anne ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3744-+
[54]   Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer [J].
Perez-Ellis, Carole ;
Goncalves, Anthony ;
Jacquemier, Jocelyne ;
Marty, Michel ;
Girre, Veronique ;
Roche, Henri ;
Brain, Etienne ;
Moatti, Jean-Paul ;
Viens, Patrice ;
Le Corroller-Soriano, Anne-Gaelle .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (05) :492-498
[55]   Use of the monoclonal antibody Anti-HER2 trastuzumab in the treatment of metastatic breast cancer - A cost-effectiveness analysis [J].
Poncet, Benedicte ;
Bachelot, Thomas ;
Colin, Cyrille ;
Ganne, Christell ;
Jaisson-Hot, Isahelle ;
Uvre, Hithert -F ;
Peaud, Pierre-Yves ;
Jacquin, Jean-Philippe ;
Salles, Bruno ;
Tigaud, Jean-Donfinique ;
Mechin-Cretinon, Aabelle ;
Marechal, Francois ;
Fournel, Cecile ;
Lenoir, Veronique Trillet .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (04) :363-368
[56]   Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer [J].
Scaltriti, Maurizio ;
Rojo, Federico ;
Ocana, Alberto ;
Anido, Judit ;
Guzman, Marta ;
Cortes, Javier ;
Di Cosimo, Serena ;
Matias-Guiu, Xavier ;
Ramon y Cajal, Santiago ;
Arribas, Joaquin ;
Baselga, Jose .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (08) :628-638
[57]   Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? [J].
Skedgel, C. ;
Rayson, D. ;
Younis, T. .
ANNALS OF ONCOLOGY, 2013, 24 (07) :1834-1840
[58]   The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial [J].
Skedgel, Chris ;
Rayson, Daniel ;
Younis, Tallal .
VALUE IN HEALTH, 2009, 12 (05) :641-648
[59]   Adjuvant Trastuzumab in HER2-Positive Breast Cancer [J].
Slamon, Dennis ;
Eiermann, Wolfgang ;
Robert, Nicholas ;
Pienkowski, Tadeusz ;
Martin, Miguel ;
Press, Michael ;
Mackey, John ;
Glaspy, John ;
Chan, Arlene ;
Pawlicki, Marek ;
Tamas Pinter ;
Valero, Vicente ;
Liu, Mei-Ching ;
Sauter, Guido ;
von Minckwitz, Gunter ;
Visco, Frances ;
Bee, Valerie ;
Buyse, Marc ;
Bendahmane, Belguendouz ;
Tabah-Fisch, Isabelle ;
Lindsay, Mary-Ann ;
Riva, Alessandro ;
Crown, John .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14) :1273-1283
[60]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792